Clinical Trial Update: A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the safety of durvalumab given after sequential chemotherapy and radiation in unresectable stage III non-small cell lung cancer; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2022-10-07